The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

NCT04263415 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication semaglutide affects taste, tongue tissue, digestion, and brain response in women who have polycystic ovary syndrome (PCOS) and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 30 people

Who can join Ages 18–50 · female only

Timeline Started 2019-11 · est. completion 2021-10

Where 1 site · Slovenia

What this study is testing ClinicalTrials.gov NCT04263415 ↗

Description as written by the study sponsor.

The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA) semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of neural response in central reward processing regions and gastric emptying rate. In addition, we aim to investigate the associations between semaglutide induced modulation of taste sensitivity, neural responses and gastric emptying with changes in body mass, eating- behavioural pattern, food perception and food intake.

Treatments tested

Semaglutide also known as Ozempic Drug

semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
Placebo Other

once-weekly injection with placebo pen for 16 weeks

Main thing measured	to investigate the effect of semaglutide on taste perception as change in taste sensitivity detected by chemical gustometry evaluated with "Taste strips" test
Sponsor	University Medical Centre Ljubljana
Conditions studied	PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome, Gastric Emptying, Central Neural Response
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04263415 ↗